Upcoming Events
  1. Australian Lung Cancer Conference 2020

    February 19, 2020 - February 21, 2020
  2. ALTG Clinical Trial Concept Development Workshop

    February 19, 2020 @ 9:30 am - 1:00 pm
  3. ALTG Open Scientific Advisory Committee Meeting

    February 19, 2020 @ 2:00 pm - 5:00 pm
  4. ALTG Open Management Advisory Committee Meeting

    February 20, 2020 @ 7:00 am - 8:00 am
  5. ALTG Strategic Planning Workshop

    February 21, 2020 @ 7:00 am - 9:00 am

ALTG Symposium & Members’ Meeting

Join us at The ALTG Lung Cancer Symposium; a one day forum for Australasian’s leading cancer health professionals to unite and  connect in with  medical scientists, healthcare professionals and consumers to understand the latest cutting-edge innovations in lung cancer research and therapeutics from those most prominent in the oncology field.

The ALTG Lung Cancer Symposium is on the 6 October and is not something to be missed. The Symposium features internationally respected guest speakers; Dr Bob Li, a Medical Oncologist from Memorial Sloan Kettering Cancer Centre in New York City, Dr Sanjay Popat, a Medical Oncologist from The Royal Marsden Hospital in London and Mr Chris Draft, Founder, President and CEO of The Chris Draft Family Foundation (CDFF) located in Atlanta, Georgia. The Foundation focusses on eight primary initiatives with overarching themes that stress the importance of education, healthy lifestyles, character development, personal responsibility, self-discipline and physical fitness. The CDFF’s newest initiative, Team Draft was created by Chris and Keasha during Keasha’s year-long struggle with Stage IV Lung Cancer. The meeting agenda can be found on the ALTG website and travel grants are available.

Please register here for the ALTG symposium https://altg.com.au/event/symposium-2018/

The ALTG Members’ Meeting will be held on October 5 October and precedes the ALTG Symposium. The day will begin with an Investigator Meeting for sites involved in the STIMULI trial (ALTG 16/012) led by Associate Prof. Paul Mitchell which is a randomised open-label phase 2 trial of consolidation with nivolumab and ipilimumab in limited-stage Small Cell Lung Cancer after chemo-radiotherapy. The purpose is to evaluate if patients treated with chemo-radiotherapy and PCI followed by consolidation treatment (nivo+ipi) have a better outcome (progressive-free survival and overall survival) compared to patients treated with chemo-radiotherapy and prophylactic cranial irradiation (PCI) alone.

The ALTG Members’ Meeting will begin after lunch with a review of current trials and concepts followed by a concept generation workshop.

Please register here to attend the ALTG Members Meeting https://altg.com.au/event/altg-members-meeting/